Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
By Hui Yang, C. Bueso-Ramos, C. Dinardo, M. Estecio, M. Davanlou, Qi-rong Geng, Zhihong Fang, M. Nguyen, S. Pierce, Yue Wei and 4 more. Leukemia, 2013
667 citations recorded by the source corpus.
Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) patients (N=124). Aberrant upregulation (⩾2-fold) was observed in 34, 14, 15 and 8% of the patients. Increased expression of these four genes was also observed in peripheral blood mononuclear cells (PBMNCs) (N=61). The relative expression of PD-L1 from PBMNC was significantly higher in MDS (P=0.018) and CMML (P=0.0128) compared with AML. By immunohistochemical analysis, PD-L1 protein expression was observed in MDS CD34+ cells, whereas stroma/non-blast cellular compartment was positive for PD-1. In a cohort of patients treated with epigenetic therapy, PD-L1, PD-L2, PD-1 and CTLA4 expression was upregulated. Patients resistant to therapy had relative higher increments in gene expression compared with patients who achieved response. Treatment of leukemia cells with decitabine resulted in a dose-dependent upregulation of above genes. Exposure to decitabine resulted in partial demethylation of PD-1 in leukemia cell lines and human samples. This study suggests that PD-1 signaling may be involved in MDS pathogenesis and resistance mechanisms to hypomethylating agents. Blockade of this pathway can be a potential therapy in MDS and AML.
Subfields: Hematology, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/b223c2cb6a97eacde7351e60bbc4495917d37b5d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Targeting FTO suppresses cancer stem cell maintenance and immune evasion (2020, positive): “Since the observations that HMA treatment induces up-regulation of PD-1/PD-L1/PD-L2 (Orskov et al., 2015; Yang et al., 2014), multiple clinical trials are ongoing now to test therapeutic potential of the combinations of HMA with anti-PD-1, PDL1, or PD-L2 antibodies for AML and MDS treatment (Alfayez”